We analysed 57 patients with non-myeloid malignancies who received a non-purged autologous PBSCT. All had similar mobilisation and conditioning regimens. A high prior chemotherapy score and the number of chemotherapy lines used (P = 0.015 and P = 0.01, respectively) were adverse predictors of CD34 cell yields. Lower CD34 values (P = 0.002) were seen in patients treated with potent stem cell toxins (BCNU, melphalan, CCNU and mustine), designated toxicity factor 4 agents (TF4). 
Prior exposure to specific cytotoxic agents and the number of cycles of chemotherapy given, are associated with a reduced peripheral blood progenitor cell yield. 1, 2 However the cumulative effects on long-term haematopoiesis of multiple cycles of combination chemotherapy are less well defined. Drake et al 3 have devised a chemotherapy scoring system (outlined in Table 1 ) in which each chemotherapy agent used was given a score based on its predicted stem cell toxicity (range 0-4). By multivariate analysis only exposure to stem cell toxicity factor 4 drugs (BCNU, melphalan, CCNU and mustine) prior to PBSC mobilisation was a significant predictor of lower CD34 counts. They did not analyse their data with respect to time to engraftment.
In order to study the effect of prior chemoradiotherapy on CD34 levels and the rate of engraftment, we calculated the chemotherapy score 3 and the number of lines of chemo-therapy modalities used in our practice. Between April 1994 and December 1997, 57 consecutive patients (10 F, 47 M) receiving the BEM preparative regimen 4 at our institution for non-myeloid malignancies were analysed. Patients transplanted before this date were excluded because CD34 enumeration was not routinely performed at that time.
Patients and methods

Patients and prior chemotherapy
Between April 1994 and December 1997, 57 patients (10 F, 47 M) received BEM conditioning and auto-PBSCT for non-myeloid malignancies. Median age at transplant was 43 years (range 16-63). Diagnoses were NHL (29), Hodgkin's (19), myeloma (7) and amyloid (2) . Fifteen different chemotherapy regimens had been previously used, all according to standard unit protocols. Thirty-one patients received one and 26 were treated with two different lines of chemotherapy prior to stem cell mobilisation. The regimens are summarised in Table 2 . Four patients had prior exposure to TF4 drugs (two with MOPP which contains mustine, and two with miniBEAM which includes BCNU and melphalan), and six received extended field radiotherapy (EFR). Using the Drake et al scoring system, 3 the median chemotherapy score for the entire group was 48 (Interquartile range: 30 to 62).
Stem cell mobilisation and CD34 enumeration
Intravenous cyclophosphamide and G-CSF (5 g/kg body weight subcutaneously) was used for PBSC mobilisation. Fifty-five patients received 3 g/m 2 cyclophosphamide and two were given 6 g/m 2 . Leucapheresis commenced when the leucocyte count reached 4.0 × 10 9 /l, using a Cobe (Lakewood, CO, USA) continuous flow cell separator as previously described. 5 Fifteen patients required one apheresis, 38 had two, two had three and two went on to four collections. No patients requiring more than one set of mobilization and collections, or receiving a combined PBSC and bone marrow transplant were included in this study. CD34 surface marker analysis was performed using anti-CD34 phycoerythrin (PE)-conjugated antibody (HPCA2; Becton Dickinson, San Jose, CA, USA) and anti-CD45 FITC-conjugated antibody (Hle-1; Becton Dickinson). Cells were analysed on a Coulter EPICS Elite and between 50 000 and 100 000 CD45-positive events were gated for CD34 positivity. Results were expressed as a percentage of the white cell count and converted to a re- /kg body weight was defined as adequate for auto-PBSCT, with levels between 1-2 × 10 6 /kg considered borderline. CFU-GMs were assayed in a semi-solid methyl cellulose culture system as previously described. 6 
Preparative regimen
All patients received: intravenous (i.v.) etoposide 2 g/m 2 as a concentrated solution via a syringe driver over 4 h with i.v. hydration on day −3; BCNU 300-450 mg/m 2 as a 2-h infusion on day −2 (with dose adjustment according to lung diffusion capacity); and melphalan 140 mg/m 2 as an i.v. push with hydration and forced diuresis on day −1. Stem cells were re-infused a minimum of 24 h following chemotherapy. Cytokines were not administered after stem cell re-infusion.
Statistics
Statistical analysis was performed using SPSS for Windows software. Correlation tests were performed using the twotailed Pearson rank correlation coefficient, and linear regression used to determine the significance of postulated predictive factors. Exposure to toxicity factor 4 drugs was categorised as a binary variable. Mean values were compared using the t-test. Engraftment was defined as a sustained neutrophil count у0.5 × 10 9 /l and unsupported platelets у50 × 10 9 /l. All patients with delayed haematopoietic Chemotherapy scoring system as devised by Drake et al. 3 The overall score is calculated from the sum total of the toxicity factors of each drug used in a given regimen, multiplied by the number of times that regimen was used, eg 6 courses of CVAD = (2 + 1 + 2 + 0) × 6 = 30. Extended field radiotherapy was awarded a score of 2. reconstitution were censored at day 100 if engraftment had not taken place by this time.
Results
Progenitor cell yield
The median CD34 count was 4.69 × 10 6 /kg (range 1.25-44.67). Six patients had values below 2.0 × 10 6 /kg (median 1.80, range 1.25-1.90). The distribution of CD34 values are shown in Figure 1 . In the 50 patients in whom CFU-GM levels were available (median 11.69 × 10 4 /kg, range 0.55-193.92) there was a significant correlation between CD34 and CFU-GM values (r = 0.5, P Ͻ 0.001).
Predictors of CD34 cell count
By linear regression analysis, the only variables predictive of CD34 cell yields were chemotherapy score (both as a continuous and as a binary variable, ie score Ͻ60 or у60, P = 0.015 and P = 0.047, respectively), and the number of lines of prior chemotherapy used (P = 0.01). Figure 2 illustrates the variation in CD34 values plotted against score, and against lines of prior chemotherapy. Other variables analysed were age (P = 0.44), sex (P = 0.45), diagnosis (myeloma vs non-myeloma) (P = 0.29) and EFR (P = 0.30). Patients with a therapy score of Ͻ60, and those treated with only one line of chemotherapy, had a significantly higher mean CD34 value than those with scores у60 and those treated with two lines (P = 0.003 and P = 0.002, respectively; independent samples t-test).
Engraftment
The median number of days to neutrophils у0.5 × 10 9 /l and unsupported platelets у50 × 10 9 /l were 13 (range 8-100) and 15 (9-100), respectively. There was no linear relationship between engraftment and CD34 counts. A greater variation in days to engraftment was seen if CD34 values were р5.0 compared to Ͼ5.0 × The duration of treatment is expressed in days, which are shown in parentheses after the drug dose, eg days 1-8 is shown as (1-8) comparison with the 53 that had not (4.9 × 10 6 /kg, range 1.43-44.67; P = 0.002). In the entire group, no variables were predictive of neutrophil engraftment but there was a significant adverse association between platelet recovery and exposure to toxicity factor 4 drugs (P = 0.007).
Discussion
We studied 57 consecutive patients, all of whom received cyclophosphamide/G-CSF priming and who subsequently received an autologous PBSCT using an identical preparative regimen. Compared with the lymphoproliferative disorders, breast cancer patients have a shorter and acute myeloid leukaemia patients a longer time, to platelet recovery. 7 Our analysis included only patients with myeloma, NHL and Hodgkin's disease. Patients requiring more than one set of mobilization procedures to achieve an adequate CD34 count have been shown to have slower platelet recovery. 8 In order to prevent the number of mobilization procedures confounding any analysis of haematopoietic reconstitution, no patients requiring more than one set of collections were included in this study. Similarly, patients receiving a combined PBSC and bone marrow transplant were also excluded. We observed no linear relationship between CD34 numbers obtained and engraftment. This is not an unexpected finding and is most likely due to a 'threshold effect' given that all patients had a CD34 yield Ͼ1.0 × 10 6 /kg. However, in agreement with previous reports, 8, 9 we found that higher progenitor cell doses were associated with more predictable haematopoietic reconstitution.
All six patients with a CD34 value between 1.0 and 2.0 × 10 6 /kg engrafted by day 51. Two of these patients had prior exposure to TF4 drugs. There was a significantly lower median number of CD34 cells obtained in TF4 recipients (P = 0.002). Additionally, and irrespective of CD34 cell numbers, there was a significant adverse association between the platelet kinetics of engraftment and exposure to TF4 (P = 0.007). These results suggest that the delay in engraftment caused by certain cytotoxics cannot be accounted for by a reduction in stem cell yield alone. One explanation is that TF4 drugs damage the bone marrow microenvironment resulting in a reduced rate of haematopoietic reconstitution. Alternatively, these cytotoxics may be more damaging to megakaryocyte precursors than to other progenitors.
In agreement with Drake et al 3 we found that prior exposure to EFR such as 'mantle' radiotherapy did not adversely reduce CD34 numbers, whereas the chemotherapy score is significantly associated with low progenitor cell values. However the number of lines of chemotherapy previously administered was equally predictive of stem cell yields and is easier to calculate.
In the Drake et al 3 study only exposure to stem cell toxicity factor 4 drugs (BCNU, melphalan, CCNU and mustine) prior to PBSC mobilisation was a significant predictor of lower CD34 counts. A prospective study of patients with relapsed NHL and Hodgkin's disease, 10 showed that salvage treatment with miniBEAM (which includes carmustine and melphalan) resulted in significantly lower CD34 yields in PBSC harvests in comparison to patients not receiving any salvage therapy prior to mobilization. In our study, we demonstrate that prior exposure to TF4 drugs is the only significant variable to be associated with delayed platelet engraftment. Therefore, we believe that potential PBSCT candidates should if possible avoid first-line and salvage chemotherapy containing known TF4 drugs. Our practice for patients with relapsed and refractory lymphomas has consequently changed from employing sal- vage chemotherapy containing known stem cell toxins (eg miniBEAM), to regimens such as DHAP (dexamethasone, ara-C and cisplatinum) 11 and IVE (ifosphamide, VP-16 and epirubicin). The latter has the added advantage of allowing stem cell collection during the leucocyte recovery phase. 12, 13 We are aware that CD34 enumeration techniques vary between centres. Values obtained depend on the methods of cell processing, on the monoclonal antibodies and fluorochrome labels used and the gating strategies employed. 14 In our institution, using the CD34 methodology described earlier, the majority of patients with CD34 values Ͼ1.0 × 10 6 /kg will have rapid and sustained haematopoietic engraftment after high-dose therapy using the BEM regimen. Above this threshold, the only predictive factor of delayed engraftment is prior exposure to stem cell toxins. In patients who have not been exposed to toxicity factor 4 agents or extensive prior chemoradiotherapy, a CD34 threshold Ͼ1.0 ϫ 10 6 /kg will be associated with engraftment, albeit delayed in some. Since prior TF4 exposure independently affects time to engraftment, higher threshold of у2.0 ϫ 10 6 /kg is recommended in these patients to ensure haematopoietic recovery. In those without an adequate cell yield, other strategies such as bone marrow harvest, 15 repeat stem cell collection or alternative mobilisation regimens using novel cytokine combinations, 16 should be considered.
